Web Desc
Protein Kinases and Cancer: The Promise of Molecular-Based Therapies
Organizer(s): Judith S. Sebolt-Leopold and Charles L. Sawyers
Date: February 24 - 29, 2004
Location: Granlibakken Tahoe, Tahoe City, CA, USA
Sponsored by Amgen Inc.
Summary of Meeting:
Upon completion of this conference, participants should be able to: - Discuss progress made in the cancer research community showing that kinases are druggable targets. - Recognize key signal transduction pathways amenable to pharmacological intervention by kinase inhibitors. - Discuss the critical importance of translational assays in driving clinical trial design of kinase-targeted therapies. - Discuss the application of technologies, encompassing proteomics, genomics, and structural biology, for facilitating novel drug discovery. - Discuss the challenges facing oncologists in deciphering the complexities of individual tumor signaling. - Integrate multidisciplinary leaders involved in basic research, pharmaceutical discovery, and clinical oncology in order to provide all with a better understanding of the numerous steps involved in going from bench to bedside. - Develop new collaborations among the scientists in attendance as well as new insights leading to novel and effective interventions.
Discounted Abstract Deadline: October 23 2003
Discounted Registration Deadline: December 23 2003
We gratefully acknowledge additional support for this conference from:

Cell Signaling Technology, Inc.
Educational donation provided by AmgenPfizer Inc.Wyeth Research Labs
We gratefully acknowledge the generous grant for this conference provided by:

National Cancer Institute (NCI)
Grant No. 1R13CA105863-01
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program

Tuesday, February 24 | 3:00PM - 7:00PM
Registration
Room: Pre-Function


Tuesday, February 24 | 7:15PM - 7:30PM
Orientation
Room: Mountain/Lake Rooms


Tuesday, February 24 | 7:30PM - 8:30PM
Keynote Address
Room: Mountain/Lake Rooms

Speaker 1 of 1
Robert E. Wittes, Memorial Sloan-Kettering Cancer Center, USA
A Clinical Perspective on the Future of Kinase-Targeted Therapies


Wednesday, February 25 | 7:00AM - 8:00AM
Breakfast
Room: Granhall


Wednesday, February 25 | 8:00AM - 11:15AM
Therapies Targeting Growth Factor Receptors: The ErbB Family
and Associated Signaling

Room: Mountain/Lake Rooms

Speaker 1 of 6
* Carlos L. Arteaga, Vanderbilt University School of Medicine, USA
Predictors of Response and Resistance to Erbb Tyrosine Kinase Inhibitors

Wednesday, February 25 | 8:00AM - 11:15AM
Therapies Targeting Growth Factor Receptors: The ErbB Family
and Associated Signaling

Room: Mountain/Lake Rooms

Speaker 2 of 6
Lewis A. Chodosh, University of Pennsylvania School of Medicine, USA
Inducible Transgenic Models for Breast Cancer Progression and Target Validation

Wednesday, February 25 | 8:00AM - 11:15AM
Therapies Targeting Growth Factor Receptors: The ErbB Family
and Associated Signaling

Room: Mountain/Lake Rooms

Speaker 3 of 6
Mark X. Sliwkowski, Genentech, Inc., USA
Targeting Ligand Activated ErbB2/HER2 in Solid Tumors

Wednesday, February 25 | 8:00AM - 11:15AM
Therapies Targeting Growth Factor Receptors: The ErbB Family
and Associated Signaling

Room: Mountain/Lake Rooms

Speaker 4 of 6
Tomi K. Sawyer, CMD BIoscience, USA
Novel Dual Src/Abl Kinase Inhibitors for Cancer Therapy

Wednesday, February 25 | 8:00AM - 11:15AM
Therapies Targeting Growth Factor Receptors: The ErbB Family
and Associated Signaling

Room: Mountain/Lake Rooms

Speaker 5 of 6
Geoffrey W. Krystal, Virginia Commonwealth University, USA
Short Talk: The Combination of STI571 and a Novel IGF-1R Kinase Inhibitor Efficiently Blocks PI3K-Akt Activity, Inhibits Growth and Promotes Apoptosis in SCLC

Wednesday, February 25 | 8:00AM - 11:15AM
Therapies Targeting Growth Factor Receptors: The ErbB Family
and Associated Signaling

Room: Mountain/Lake Rooms

Speaker 6 of 6
Sang Hoon Lee, ABL Bio, South Korea
Short Talk: In vivo Anti-Angiogenic and Anti-Tumor Activity is Associated with Target Modulation by CHIR258, a Small Molecule Inhibitor of Receptor Tyrosine Kinases

Wednesday, February 25 | 9:20AM - 9:40AM
Coffee Break
Room: Pre-Function


Wednesday, February 25 | 11:15AM - 1:00PM
Poster Setup
Room: Bay Room


Wednesday, February 25 | 1:00PM - 10:00PM
Poster Viewing
Room: Bay Room


Wednesday, February 25 | 4:30PM - 5:00PM
Coffee & Snacks Available
Room: Pre-Function


Wednesday, February 25 | 5:00PM - 7:15PM
Additional Kinase Approaches with Therapeutic Promise
Room: Mountain/Lake Rooms

Speaker 1 of 4
* Douglas Hanahan, ISREC, Switzerland
An Overview of Angiogenic-Directed Approaches

Wednesday, February 25 | 5:00PM - 7:15PM
Additional Kinase Approaches with Therapeutic Promise
Room: Mountain/Lake Rooms

Speaker 2 of 4
George F. Vande Woude, Van Andel Research Institute, USA
Met-HGF/SF in Human Malignancy

Wednesday, February 25 | 5:00PM - 7:15PM
Additional Kinase Approaches with Therapeutic Promise
Room: Mountain/Lake Rooms

Speaker 3 of 4
Anita B. Roberts, National Institutes of Health, USA
TGF-beta/Smad Signaling: Dual Tumor Suppressor and Pro-Metastatic Activities

Wednesday, February 25 | 5:00PM - 7:15PM
Additional Kinase Approaches with Therapeutic Promise
Room: Mountain/Lake Rooms

Speaker 4 of 4
Jonathan M. Yingling, Idera Pharmaceuticals, Inc., USA
TGF-beta Receptor Kinase Inhibitors: A Novel Cancer Therapy

Wednesday, February 25 | 7:15PM - 8:15PM
Dinner
Room: Granhall


Wednesday, February 25 | 8:00PM - 10:30PM
Poster Session 1
Room: Bay Room


Wednesday, February 25 | 8:00PM - 9:00PM
Social Hour
Room: Bay Room


Thursday, February 26 | 7:00AM - 8:00AM
Breakfast
Room: Granhall


Thursday, February 26 | 8:00AM - 11:00AM
The MAP Kinase Pathway: Multiple Targets for Pharmacological
Intervention

Room: Mountain/Lake Rooms

Speaker 1 of 5
Daniel G. Gioeli, University of Virginia, USA
Signal Transduction in Prostate Cancer Progression

Thursday, February 26 | 8:00AM - 11:00AM
The MAP Kinase Pathway: Multiple Targets for Pharmacological
Intervention

Room: Mountain/Lake Rooms

Speaker 2 of 5
* Judith Sebolt-Leopold, USA
Attractiveness of Targeting MEK for Anticancer Drug Development


Thursday, February 26 | 8:00AM - 11:00AM
The MAP Kinase Pathway: Multiple Targets for Pharmacological
Intervention

Room: Mountain/Lake Rooms

Speaker 3 of 5
Richard M. Marais, Cancer Research UK Manchester Institute, UK
B-Raf Mutations in Human Cancer: Implications for Development of
Improved Therapies


Thursday, February 26 | 8:00AM - 11:00AM
The MAP Kinase Pathway: Multiple Targets for Pharmacological
Intervention

Room: Mountain/Lake Rooms

Speaker 4 of 5
Michelle Renee Ward, Chiron Corporation, USA
Short Talk: Amplification of B-raf in Melanoma Cell Lines Identified Using Array Comparative Genomic Hybridization (aCGH)

Thursday, February 26 | 8:00AM - 11:00AM
The MAP Kinase Pathway: Multiple Targets for Pharmacological
Intervention

Room: Mountain/Lake Rooms

Speaker 5 of 5
Rosalie C. Sears, Oregon Health & Science University, USA
Short Talk: c-Myc Protein Degradation is Regulated by Ras Signaling Pathways, the PP2A Phosphatase and the Pin1 Prolyl Isomerase

Thursday, February 26 | 9:20AM - 9:40AM
Coffee Break
Room: Pre-Function


Thursday, February 26 | 11:00AM - 1:00PM
Poster Setup
Room: Bay Room


Thursday, February 26 | 1:00PM - 10:00PM
Poster Viewing
Room: Bay Room


Thursday, February 26 | 4:30PM - 5:00PM
Coffee & Snacks Available
Room: Pre-Function


Thursday, February 26 | 5:00PM - 7:00PM
Cell Cycle Targets
Room: Mountain/Lake Rooms

Speaker 1 of 4
* Edward Harlow, Constellation Pharmaceuticals, USA
Synergy between Signaling Pathways

Thursday, February 26 | 5:00PM - 7:00PM
Cell Cycle Targets
Room: Mountain/Lake Rooms

Speaker 2 of 4
Peter L. Toogood, Lycera Corporation, USA
Discovery of A Selective CDK4 Inhibitor

Thursday, February 26 | 5:00PM - 7:00PM
Cell Cycle Targets
Room: Mountain/Lake Rooms

Speaker 3 of 4
Nicholas J. Keen, Novartis Institutes for BioMedical Research, USA
Targeting Cytokinesis and the Cell Cycle: Aurora B and CDK1/2 as Unique Targets in Cancer

Thursday, February 26 | 5:00PM - 7:00PM
Cell Cycle Targets
Room: Mountain/Lake Rooms

Speaker 4 of 4
Martin J.I. Andrews, Cyclacel, Ltd., UK
Short Talk: Inhibition of CDK2- Cyclin A Activity by Blocking Substrate Recruitment

Thursday, February 26 | 7:00PM - 8:00PM
Dinner
Room: Bay Room


Thursday, February 26 | 8:00PM - 10:30PM
Poster Session 2
Room: Bay Room


Thursday, February 26 | 8:00PM - 9:00PM
Social Hour
Room: Bay Room


Friday, February 27 | 7:00AM - 8:00AM
Breakfast
Room: Granhall


Friday, February 27 | 8:00AM - 11:15AM
Survival Signaling: The AKT/PI 3-Kinase Pathway
Room: Mountain/Lake Rooms

Speaker 1 of 5
Gordon B. Mills, University of Texas MD Anderson Cancer Center, USA
Targeting the PI3K Pathway in Cancer

Friday, February 27 | 8:00AM - 11:15AM
Survival Signaling: The AKT/PI 3-Kinase Pathway
Room: Mountain/Lake Rooms

Speaker 2 of 5
Philip N. Tsichlis, Tufts-New England Medical Center, USA
TPL-2 on a Cancer Target

Friday, February 27 | 8:00AM - 11:15AM
Survival Signaling: The AKT/PI 3-Kinase Pathway
Room: Mountain/Lake Rooms

Speaker 3 of 5
* Neal Rosen, Memorial Sloan-Kettering Cancer Center, USA
Inhibition of AKT Activation with Ansamycins


Friday, February 27 | 8:00AM - 11:15AM
Survival Signaling: The AKT/PI 3-Kinase Pathway
Room: Mountain/Lake Rooms

Speaker 4 of 5
Paul Workman, Institute of Cancer Research, UK
Drugging the Cancer Chaperone: Laboratory and Clinical Advances in Targeting Heat Shock Protein 90 (Hsp90)

Friday, February 27 | 8:00AM - 11:15AM
Survival Signaling: The AKT/PI 3-Kinase Pathway
Room: Mountain/Lake Rooms

Speaker 5 of 5
Jeremy R. Graff, Eli Lilly and Company, USA
Short Talk: Anti-Tumor Activity of the PKCbeta Selective Inhibitor, LY317615: Inhibition of the PI3 Kinase/ AKT Pathway by the Primary Metabolite, LY326020

Friday, February 27 | 9:20AM - 9:40AM
Coffee Break
Room: Pre-Function


Friday, February 27 | 11:15AM - 1:00PM
Poster Setup
Room: Bay Room


Friday, February 27 | 1:00PM - 10:00PM
Poster Viewing
Room: Bay Room


Friday, February 27 | 4:30PM - 5:00PM
Coffee & Snacks Available
Room: Pre-Function


Friday, February 27 | 5:00PM - 7:00PM
Survival Signaling: Inhibition of mTOR(FRAP)
Room: Mountain/Lake Rooms

Speaker 1 of 4
* Manuel Hidalgo, Johns Hopkins School of Medicine, USA
Overview of mTOR Biology and Therapeutic Approaches

Friday, February 27 | 5:00PM - 7:00PM
Survival Signaling: Inhibition of mTOR(FRAP)
Room: Mountain/Lake Rooms

Speaker 2 of 4
Pamela S. Cohen, Amo Therapeutics, USA
The Clinical Promise of mTOR Targeted Therapy

Friday, February 27 | 5:00PM - 7:00PM
Survival Signaling: Inhibition of mTOR(FRAP)
Room: Mountain/Lake Rooms

Speaker 3 of 4
James J. Gibbons Jr., Wyeth Pharmaceuticals, USA
Enhanced Sensitivity of PTEN-Deficient Tumors to mTOR Inhibition

Friday, February 27 | 5:00PM - 7:00PM
Survival Signaling: Inhibition of mTOR(FRAP)
Room: Mountain/Lake Rooms

Speaker 4 of 4
Amy M. Mingo-Sion, University of Colorado Health Sciences Center, USA
Short Talk: Mammalian Target of Rapamycin Predominantly Regulates Insulin Receptor Substrate-1 Ser312 Phosphorylation in Breast Cancer Cells

Friday, February 27 | 7:00PM - 8:00PM
Dinner
Room: Granhall


Friday, February 27 | 8:00PM - 10:30PM
Poster Session 3
Room: Bay Room


Friday, February 27 | 8:00PM - 9:00PM
Social Hour
Room: Bay Room


Saturday, February 28 | 7:00AM - 8:00AM
Breakfast
Room: Granhall


Saturday, February 28 | 8:00AM - 11:15AM
Impact of Technologies on Future Target Identification
Room: Mountain/Lake Rooms

Speaker 1 of 6
John Kuriyan, University of California, Berkeley, USA
Auto-Regulation Mechanisms in c-Abl Tyrosine Kinase


Saturday, February 28 | 8:00AM - 11:15AM
Impact of Technologies on Future Target Identification
Room: Mountain/Lake Rooms

Speaker 2 of 6
Keith P. Wilson, Takeda California, USA
Structures of Active Autoinhibited and Gleeve-Bond C-KIT

Saturday, February 28 | 8:00AM - 11:15AM
Impact of Technologies on Future Target Identification
Room: Mountain/Lake Rooms

Speaker 3 of 6
Natalie G. Ahn, University of Colorado, USA
A Functional Proteomics Approach to Target Identification


Saturday, February 28 | 8:00AM - 11:15AM
Impact of Technologies on Future Target Identification
Room: Mountain/Lake Rooms

Speaker 4 of 6
* William R. Sellers, Broad Institute of MIT and Harvard, USA
Phenotypic Screening of Small Molecule Libraries

Saturday, February 28 | 8:00AM - 11:15AM
Impact of Technologies on Future Target Identification
Room: Mountain/Lake Rooms

Speaker 5 of 6
X. Helen Hua, Enfunding Solution Inc, USA
Short Talk: Enhancing Discovery of Selective Small Molecule Akt Inhibitors Using Biomarkers

Saturday, February 28 | 8:00AM - 11:15AM
Impact of Technologies on Future Target Identification
Room: Mountain/Lake Rooms

Speaker 6 of 6
J. Guillermo Paez, Dana Farber Cancer Institute, USA
Short Talk: Kinome Re-Sequencing in Human Cancer

Saturday, February 28 | 9:00AM - 12:00PM
Entertainment
Room: Mountain/Lake Rooms


Saturday, February 28 | 9:20AM - 9:40AM
Coffee Break
Room: Pre-Function


Saturday, February 28 | 4:30PM - 5:00PM
Coffee & Snacks Available
Room: Pre-Function


Saturday, February 28 | 5:00PM - 7:00PM
Looking Forward: The Impact of Kinase-Targeted Therapies on
Patient Survival

Room: Mountain/Lake Rooms

Speaker 1 of 3
Roger G. Ulrich, RUC Pharmaceutical Development Specialists, USA
Molecular Profiling of Adverse Drug Effects

Saturday, February 28 | 5:00PM - 7:00PM
Looking Forward: The Impact of Kinase-Targeted Therapies on
Patient Survival

Room: Mountain/Lake Rooms

Speaker 2 of 3
Christopher E. Sims, University of California, Irvine, USA
Short Talk: Advancing the Field of Signal Transduction One Cell at a Time: Analysis of Single Tumor Cells Using the Laser Micropipet System

Saturday, February 28 | 5:00PM - 7:00PM
Looking Forward: The Impact of Kinase-Targeted Therapies on
Patient Survival

Room: Mountain/Lake Rooms

Speaker 3 of 3
* Charles L. Sawyers, Memorial Sloan-Kettering Cancer Center, USA
Clinical Reality: How do Oncologists Screen for Signaling Abnormalities?

Saturday, February 28 | 7:00PM - 8:00PM
Social Hour
Room: Granhall


Saturday, February 28 | 8:00PM - 9:00PM
Dinner
Room: Mountain/Lake Rooms


Sunday, February 29 | 10:26AM - 10:26AM
Departure


*Session Chair.